Imugene Ltd · ASX:IMU
Imugene — Shareholder Meeting (November 2021)
11 slides from Imugene's shareholder meeting presentation, Nov 19, 2021
Slide 1: Imugene AGM 2021
For personal use only ASX: IMU IMUGENE AGM 2021
Slide 2: Experienced Management Team with Significant Clinical Development Expertise
Experienced Management Team with Significant Clinical Development Expertise For personal use only Imugene has a team with oncology clinical development experience Dr Rita Laeufle Dr Monil Shah Dr Nick Ede Dr Anthony Good Amanda Seiz Bonnie Nixon CALIFORNIA, USA NEW JERSEY, USA MELBOURNE, AUS SYDNEY,
Slide 3: Three Novel Technology Platforms
Three Novel Technology Platforms For personal use only onCARlytics CF33 Oncolytic Virus B Cell Immunotherapy CHECKvacc CF33-CD19 CAR T Combination Therapy VAXINIA HER-Vaxx PD1-Vaxx “Armed” PD-L1 Parental Virus Virus TIGIT-Vaxx, PDL1-Vaxx, LAG3-Vaxx, TIM3-Vaxx, VEGF-Vaxx, CTLA4-Vaxx etc 3
Slide 4: HER-Vaxx Year in Review
2 0 21 Y E A R I N R E V I E W HER-Vaxx For personal use only • HERIZON: Phase 2 Interim Results with positive OS • HERIZON: Enrollment Completed • Presentations at AACR, ASCO and ESMO World GI • HERIZON: PFS endpoint reached • HER-Vaxx patent granted in Japan • 3 New Phase 2 Gastric Studies: neoHER
Slide 5: PD1-Vaxx Year in Review
2 0 21 Y E A R I N R E V I E W PD1-Vaxx For personal use only • PD1-Vaxx FDA IND granted in the USA • IMPRINTER (Phase 1 Study): All 6 sites open in the USA and Australia • Presentation at ESMO • IMPRINTER (Phase 1 Study): Currently at the highest dose cohort Current Status MILESTONES 1st Patient Do
Slide 6: CHECKvacc Year in Review
2 0 21 Y E A R I N R E V I E W CHECKvacc For personal use only • CHECKvacc FDA IST IND granted in the USA • Presentation at AACR • CHECKvacc First Patient Dosed at COH COHORT | 3-6 PATIENTS Identify: COHORT | 3-6 PATIENTS Recommended Phase 2 Dose (RP2D) Metastatic Triple Negative COHORT | 3-6 PATIEN
Slide 7: onCARlytics Year in Review
2 0 21 Y E A R I N R E V I E W onCARlytics For personal use only • Licensed a CD19 oncolytic virus invented by Professor Yuman Fong and Dr Saul 1 Priceman from City of Hope to turn CAR-T therapy against solid tumours 4 • Exclusive strategic partnership to combine onCARlytics with Celularity’s alloge
Slide 8: 2021 Imugene Summary
2021 Imugene Summary For personal use only September 2021 S&P September February June 2021 July 2021 Quarterly Re-balance November 2021 2021 CHECKvacc $95m Toal Imugene enters PD1-Vaxx dose receives FDA IND Capital Raise ASX300 Strategic Partnership escalates to &SPP with Eureka cohort 2 August May
Slide 9: Milestones
Milestones Technology Milestone For personal use only onCARlytics 1st Patient Dosed onCARlytics FDA IND Clearance PD1-Vaxx Combination RP2D Next 12-24 months onCARlytics GLP Toxicology Study VAXINIA 1st Patient Dosed onCARlytics FDA Pre-IND Meeting onCARlytics GMP manufacturing for pre-clinical toxi
Slide 10: Financial Summary
Financial Summary Public Market Overview (17/11/21) Share Price Performance (last 12 months) For personal use only Share Price A$0.54 0.70 52 week range 0.089 - 0.625 0.60 Market Capitalisation1 A$3.063B 0.50 Cash equivalents (30 Sept 21) A$112.2M Enterprise Value A$2.946B 0.40 Top 5 Shareholders (a
Slide 11: Imugene Limited
For personal use only ASX: IMU IMUGENE LIMITED www.imugene.com info@imugene.com